1 in 5 TB Survivors Develop COPD Within 11 Years, Shows Long-Term Korean Study

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2025-06-30 23:30 GMT   |   Update On 2025-07-01 06:46 GMT
Advertisement

South Korea: A new multicenter study from South Korea has identified critical risk factors contributing to the development of chronic obstructive pulmonary disease (COPD) in individuals treated for tuberculosis (TB), emphasizing the need for long-term respiratory monitoring. Published in the International Journal of Chronic Obstructive Pulmonary Disease, the research was led by Dr. Dong-Hyun Joo and colleagues from the Seoul National University Bundang Hospital. It sheds light on the incidence and predictors of TB-associated COPD over an extended follow-up period.

The study followed 351 patients across four Korean hospitals who had received anti-tuberculosis treatment for more than six months. These individuals were monitored over 11 years (132 months) to determine the incidence and risk factors for COPD following TB treatment. Data collection included clinical records, radiologic evaluations, and lung function tests, with statistical analyses conducted to assess incidence trends and identify predictive factors.

Over the study period, 71 participants were diagnosed with TB-associated COPD, corresponding to an overall incidence of 20.56 cases per 1,000 person-years. Patients who developed COPD were generally older at the time of their TB diagnosis, had a history of smoking, and demonstrated lower baseline lung function, particularly reduced forced expiratory volume in one second (FEV₁) and FEV₁/forced vital capacity ratios.

Key Findings:

  • The incidence of COPD was significantly lower 11 years after tuberculosis treatment, with an incidence rate ratio of 0.49 compared to earlier periods.
  • Older age at the time of tuberculosis diagnosis was associated with a higher risk of developing COPD (aOR 1.04).
  • A baseline forced expiratory volume in 1 second (FEV₁) of less than 80% significantly increased the risk of COPD (aOR 3.98).
  • A history of smoking was linked to a higher likelihood of developing COPD (aOR 3.23).
  • Multilobar involvement of the lungs during tuberculosis infection was also a significant risk factor for COPD (aOR 2.04).

These findings emphasize the long-term pulmonary implications of TB, especially for individuals with compromised lung function or additional risk exposures. While the incidence declines more than a decade after treatment, the risk remains significant during the early post-treatment years, calling for targeted respiratory surveillance.

The study’s authors acknowledged certain limitations. COPD diagnosis was based solely on a fixed FEV₁/FVC ratio threshold (<0.7) without incorporating clinical symptoms. A few patients (2.2%) underwent spirometry without bronchodilator use, and CT scans were interpreted independently at each hospital without centralized review, potentially introducing variability.

Despite these constraints, the findings highlight the need for long-term lung function monitoring among high-risk TB survivors. The authors advocate for routine spirometry assessments for at least 11 years following TB treatment, especially in older patients, smokers, or those presenting with extensive lung involvement.

The authors concluded, "Further prospective studies with standardized imaging and extended follow-up are necessary to refine screening protocols and guide early interventions for TB-related COPD, ultimately aiming to reduce the burden of chronic respiratory disease in this vulnerable population."

Reference:

Joo DH, Kim MC, Sin S, Kang HR, Song JH, Kim HJ, Song MJ, Kwon BS, Kim YW, Lee YJ, Park JS, Lee JH, Lee YJ. Incidence and Risk Factors of Tuberculosis-Associated Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2025;20:2091-2102 https://doi.org/10.2147/COPD.S523732

Tags:    
Article Source : International Journal of Chronic Obstructive Pulmonary Disease

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News